J. Goldman & Co’s Wave Life Sciences WVE Stock Holding History

J. Goldman & Co’s Portfolio WVE Stock Details WVE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-53,896	Closed	-$391K	–	957
2026 Q1	$391K	Buy	53,896 +134	+0.2%	+$1.75K	0.01%	535
2025 Q4	$914K	Buy	+53,762	New	+$546K	0.02%	395
2019 Q1	–	Sell	-42,360	Closed	-$1.78M	–	334
2018 Q4	$1.78M	Buy	+42,360	New	+$1.88M	0.14%	148

Other funds holding WVE

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

GSK plc London $602M AUM

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

RAM

Readystate Asset Management Chicago, Illinois $2.93B AUM 18.57% 1-Year Est. Return

J. Goldman & Co's WVE Position: Q2 2026 in Review

J. Goldman & Co sold out of Wave Life Sciences (WVE) in Q2 2026, closing a stake of 53,896 shares — an estimated $391K sold.

J. Goldman & Co first reported a position in WVE in Q4 2018 and held it in 3 quarters. The position peaked at $1.78M in Q4 2018. 239 funds tracked by Wall St. Rank hold WVE as of Q2 2026.

J. Goldman & Co reported no remaining Wave Life Sciences position as of Q2 2026 after selling out during the quarter.
J. Goldman & Co sold 53,896 Wave Life Sciences shares in Q2 2026, an estimated $391K.
J. Goldman & Co first reported a position in Wave Life Sciences in Q4 2018 and held it in 3 quarters.
J. Goldman & Co's Wave Life Sciences position peaked at $1.78M in Q4 2018.
239 funds tracked by Wall St. Rank held Wave Life Sciences as of Q2 2026.

Based on J. Goldman & Co's 13F filing for Q2 2026, filed 14 Aug 2026.